Elizabeth Harrington received her master's degree in Human Genetics and Genetic Counseling from the Stanford School of Medicine and her BA in Biology with a minor in Communicative Disorders from the University of Redlands. Ms. Harrington is a neurogenetics clinical and research genetic counselor with expertise in Motor Neuron Disease (MND). She provides genetic counseling and testing for those neuromuscular diseases, primarily with Amyotrophic Lateral Sclerosis (ALS).Ms. Harrington directs the ALS Families Project research study, a presymptomatic natural history study designed to understand the genetic underpinnings of genetic forms of ALS and the impact on affected families. In addition to overseeing the longitudinal component of the study, she provides predictive genetic counseling services to asymptomatic individuals who are at risk of having inherited an ALS-associated genetic variant. Ms. Harrington is the Pre-Clinical Silence ALS Program genetic counselor and coordinator, a study aimed to discover and develop personalized experimental antisense oligonucleotide (ASO) medicines for ALS patients with rare, disease-causing gene mutations.Ms. Harrington joined the Department of Neurology faculty in 2019 and is a Lecturer in Genetic Counseling. She is the course director for Biochemical Genetics and Neurogenetics Fieldwork Supervisor for the master's degree program in Genetic Counseling at the Columbia University Vagelos College of Physicians and Surgeons.Ms. Harrington directs the ALS Families Project research study, a presymptomatic natural history study designed to understand the genetic underpinnings of genetic forms of ALS and the impact on affected families. In addition to overseeing the longitudinal component of the study, she provides predictive genetic counseling services to asymptomatic individuals who are at risk of having inherited an ALS-associated genetic variant. Ms. Harrington is the Pre-Clinical Silence ALS Program genetic counselor and coordinator, a study aimed to discover and develop personalized experimental antisense oligonucleotide (ASO) medicines for ALS patients with rare, disease-causing gene mutations.Ms. Harrington joined the Department of Neurology faculty in 2019 and is a Lecturer in Genetic Counseling. She is the course director for Biochemical Genetics and Neurogenetics Fieldwork Supervisor for the master's degree program in Genetic Counseling at the Columbia University Vagelos College of Physicians and Surgeons.